Chemotherapy Foundation Symposium XXVI: Innovative cancer therapy for tomorrow - Chronic myelogenous leukemia: Is there hope after therapeutic failure with imatinib (Gleevec)?

Marvin M. Goldenberg, Jorges Cortes

Research output: Contribution to journalArticle

Abstract

Studies of other inhibitors, such as PHA-739358, AP-24534, and DCC-2036, are expected to begin shortly. Each agent that was described in this section offers hope in cases of treatment failure with imatinib. The major challenges are to prevent the development of imatinib resistance and to find ways to eradicate all evidence of disease in all patients.

Original languageEnglish (US)
Pages (from-to)714-719
Number of pages6
JournalP and T
Volume33
Issue number12
StatePublished - Dec 1 2008
Externally publishedYes

Fingerprint

Investigational Therapies
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Drug Therapy
Treatment Failure
Neoplasms
Therapeutics
Imatinib Mesylate
danusertib
ponatinib
DCC-2036

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

@article{4fe0c732d03041e8bf2def86d0d1dfbb,
title = "Chemotherapy Foundation Symposium XXVI: Innovative cancer therapy for tomorrow - Chronic myelogenous leukemia: Is there hope after therapeutic failure with imatinib (Gleevec)?",
abstract = "Studies of other inhibitors, such as PHA-739358, AP-24534, and DCC-2036, are expected to begin shortly. Each agent that was described in this section offers hope in cases of treatment failure with imatinib. The major challenges are to prevent the development of imatinib resistance and to find ways to eradicate all evidence of disease in all patients.",
author = "Goldenberg, {Marvin M.} and Jorges Cortes",
year = "2008",
month = "12",
day = "1",
language = "English (US)",
volume = "33",
pages = "714--719",
journal = "P and T",
issn = "1052-1372",
publisher = "MediMedia USA Inc.",
number = "12",

}

TY - JOUR

T1 - Chemotherapy Foundation Symposium XXVI

T2 - Innovative cancer therapy for tomorrow - Chronic myelogenous leukemia: Is there hope after therapeutic failure with imatinib (Gleevec)?

AU - Goldenberg, Marvin M.

AU - Cortes, Jorges

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Studies of other inhibitors, such as PHA-739358, AP-24534, and DCC-2036, are expected to begin shortly. Each agent that was described in this section offers hope in cases of treatment failure with imatinib. The major challenges are to prevent the development of imatinib resistance and to find ways to eradicate all evidence of disease in all patients.

AB - Studies of other inhibitors, such as PHA-739358, AP-24534, and DCC-2036, are expected to begin shortly. Each agent that was described in this section offers hope in cases of treatment failure with imatinib. The major challenges are to prevent the development of imatinib resistance and to find ways to eradicate all evidence of disease in all patients.

UR - http://www.scopus.com/inward/record.url?scp=58449125189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58449125189&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:58449125189

VL - 33

SP - 714

EP - 719

JO - P and T

JF - P and T

SN - 1052-1372

IS - 12

ER -